Promethazine vs. Lorazepam for Treatment of Vertigo
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Apr 4, 2013
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 years or older
- • Background history of positional vertigo
- Exclusion Criteria:
- • Unable to provide informed consent
- • Pregnant or possibly pregnant
- • Known allergy to study medications
- • Use of antiemetic agents in the previous 24 hours
- • Evidence of drug-induced vertigo or orthostatic hypotension
- • Central pathologies/central origin for vertigo
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, Nezam Abad, Iran, Islamic Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials